Xbrane Biopharma Q1’22: Steadily Approaching Commercialization - Redeye

Redeye leaves its view on Xbrane Biopharma following today’s Q1, confirming that a BLA submission to the FDA took place at the end of March. We maintain our optimistic view of the case but slightly postpone the anticipated launch of Xlucane in the US and Europe and adjust our fair value range accordingly.

Länk till analysen i sin helhet: https://www.redeye.se/research/840807/xbrane-biopharma-q122-steadily-approaching-commercialization?utm_source=finwire&utm_medium=RSS